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PERAMALAN DISLIPIDEMIA TIDAK TERKAWAL DALAM 
KALANGAN PESAKIT JANTUNG YANG MENERIMA 
RAWATAN SEBAGAI PESAKIT LUAR DAN KESAN ADVERS 
TERHADAP EKSIPIEN FARMASEUTIKAL 
ABSTRAK
Dislipidemia tidak terkawal masih merupakan masalah yang sukar ditangani semasa 
rawatan pesakit jantung. Beberapa penulis menyatakan terdapat sumbangan 
kepatuhan pesakit, amalan pakar perubatan dan bahan aktif untuk mencapai matlamat 
kawalan dislipidemia, akan tetapi tiada pernyataan yang menyebut tentang 
sumbangan gabungan semua sebab-sebab ini. Malangnya, hanya sedikit kajian 
membincangkan kesan-kesan eksipien farmaseutikal dalam amalan klinikal dan 
terutamanya dislipidemia. Objektif kajian ini adalah untuk menentukan prediktor-
prediktor bagi dislipidemia tidak terkawal, profil lipid yang lemah, kesan advers 
ubat-ubatan (ADRs), dan kesan-kesan eksipien farmaseutikal. Yang kedua adalah 
pelaksanaan satu kaedah intervensi untuk menambah baik pengetahuan profesional 
kesihatan berkaitan eksipien farmaseutikal. Objektif pertama telah dijalankan di 
Klinik Kardiologi, Hospital Pulau Pinang di Malaysia, manakala yang kedua telah 
dilaksanakan di Hospital Pulau Pinang (Malaysia) dan Hospital Pengajaran Al-
Kadhimiya (Iraq). Kawalan dislipidemia dan profil lipid telah dinilai berdasarkan 
garis panduan Program Pendidikan Kolesterol Kebangsaan (National Cholestrol 
Education Program-NCEP). Soal selidik yang disahkan telah dijawab oleh pesakit 
untuk menentukan kepatuhan mereka dan kesan advers (ADRs) yang biasa berlaku 
semasa rawatan. Profesional kesihatan telah menjawab soal selidik yang telah 
disahkan; satu adalah untuk pakar perubatan bagi menentukan amalan mereka 
berkaitan kawalan dislipidemia, dan satu lagi adalah untuk menilai pengetahuan 
mereka mengenai eksipien farmaseutikal. Lain-lain maklumat seperti ciri-ciri pesakit, 
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ubat-ubatan yang diambil bersama, penyakit-penyakit, dan profil lipid diperolehi
daripada fail kemajuan pesakit. Maklumat mengenai eksipien farmaseutikal didapati
daripada risalah ubat-ubatan, syarikat pengilang dan Unit Maklumat Ubat hospital 
berkenaan. Pakej Statistik untuk Sains Sosial (Statistical Package for the Social 
Sciences - SPSS) versi 18 digunakan dengan ujian khi-kuasa dua (chi-square),
regresi logistik berganda (multiple logistic regression) dan laporan nisbah ganjil 
(odd ratio - OR), Mann-Whitney, Wilcoxon signed ranks test, dan regresi ordinal 
(ordinal regression). Keputusan dengan nilai p kurang daripada 0.05 dianggap 
sebagai penting. Seramai 504 orang pesakit jantung warganegara Malaysia yang 
menerima rawatan sebagai pesakit luar didaftarkan dalam kajian ini, kebanyakan 
mereka adalah lelaki (76.4%) dan Melayu (40.5%) dengan umur purata 58 ± 49 
tahun. Peratus pesakit yang mencapai sasaran kawalan dislipidemia adalah 47.2% 
dan 45.4% untuk LDL dan bukan-HDL masing-masing. Peratus penilaian profil lipid 
yang optimal, normal dan diingini adalah 37.5%, 50.1%, 61.7% dan 57% untuk LDL, 
HDL, TC dan TG masing-masing. Kejadian tertinggi ADRs yang diperhatikan dalam
sakit sendi (50.6%), manakala ADR yang ringan, sederhana dan teruk yang biasa 
dilaporkan adalah batuk (37.3%), kerap membuang air kecil (18.2%), dan kekebasan
(5.4%) masing-masing. Terdapat 10 eksipien sahaja dan 15 eksipien dengan bahan 
aktif yang menghasilkan polifarmasi. ADRs sederhana dan teruk ditemui apabila 
bilangan bahan-bahan melebihi 11 dan 15 masing-masing. Terdapat peningkatan 
yang ketara selepas intervensi dilakukan kepada profesional kesihatan dengan 
penambahbaikan yang boleh diterima dalam aspek pengetahuan am, ADRs, 
kontraindikasi dan interaksi eksipien. Kesimpulannya, kurang daripada separuh 
pesakit jantung berada di bawah kawalan dislipidemia yang dipengaruhi oleh 
pengkhususan dan pengalaman pakar perubatan, kepatuhan pesakit, bahan aktif ubat-
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ubatan dan eksipien. Pelaporan kendiri pesakit adalah alat yang sesuai untuk 
mengumpulkan ADRs yang dipengaruhi oleh ciri-ciri pesakit, penyakit lain yang 
dihidapi, dan bahan aktif ubat-ubatan serta eksipien. Polifarmasi eksipien mesti 
diambil kira apabila menjalankan kajian klinikal. Selain itu, program intervensi 
diperlukan untuk menambahbaik pengetahuan profesional kesihatan berkaitan 
eksipien farmaseutikal.
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PREDICTION OF UNCONTROLLED DYSLIPIDEMIA OF 
CARDIAC OUTPATIENTS AND THE ADVERSE EFFECT OF 
PHARMACEUTICAL EXCIPIENTS
ABSTRACT
Uncontrolled dyslipidemia is still a difficult problem to be achieved during therapy 
of cardiac patients. Several authors stated contribution of patients’ adherence, 
physicians’ practice and active ingredients to attain goals of dyslipidemia control, but 
none combined all these causes. Unfortunately few studies discussed the effects of 
pharmaceutical excipients in clinical practice and especially dyslipidemia. Objectives 
of this study were to determine predictors of uncontrolled dyslipidemia, poor lipid 
profile, adverse drug reactions (ADRs), and effects of pharmaceutical excipients.
Second is implementation of an intervention tool to improve the knowledge of 
healthcare professionals about pharmaceutical excipients. First objective was carried 
out at Cardiac Clinic of Hospital Pulau Pinang in Malaysia, while the second was 
conducted at Hospital Pulau Pinang (Malaysia) and Al-Kadhimiya Teaching Hospital
(Iraq). Dyslipidemia control and lipid profile were evaluated depending on the 
National Cholesterol Education Program (NCEP) guideline. Validated questionnaires 
were filled by patients to determine their adherence and common ADRs during 
therapy. Healthcare professionals answered validated questionnaires; one for 
physicians to determine their practice for dyslipidemia control, and another to assess 
their knowledge about pharmaceutical excipients. Other information like patients’ 
characteristics, concurrent medications, diseases, and lipid profile were collected 
from patients’ progress files. Information of pharmaceutical excipients was obtained
from medications’ leaflets, manufactured companies and Drug Information Center
(DIC) of the Hospital. Statistical Package for the Social Sciences (SPSS) version 18 
was used with chi-square, multiple logistic regression and reporting odd ratio (OR), 
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Mann-Whitney, Wilcoxon signed ranks test, and ordinal regression. Results with p
value less than 0.05 considered as significant. There were 504 Malaysian cardiac 
outpatients enrolled in current study, majority of them were males (76.4%) and 
Malays (40.5%) with mean age 58 ± 49 years. Percentage of patients who achieved
the targets of dyslipidemia control was 47.2% and 45.4% for LDL and non-HDL 
respectively. Percentages of optimal, normal or desired lipid profile evaluation were
37.5%, 50.1%, 61.7% and 57% for LDL, HDL, TC and TG, respectively. Highest 
incidence of ADRs observed in joint pain (50.6%), while the common reported mild, 
moderate and severe ADR was cough (37.3%), frequent urination (18.2%) and 
numbness (5.4%), respectively. The polypharmacy of pharmaceutical excipients was 
10 (alone) or 15 (with active ingredients). Moderate and severe ADRs found when
number of ingredients exceeded 11 and 15 respectively. There was significant 
enhancement found after intervention done to healthcare professionals with 
acceptable improvements in general knowledge, ADRs, contraindications and 
interactions of excipients. In conclusion, less than half of cardiac patients were under 
dyslipidemia control which influenced by physicians’ specialty and experience, 
patients’ adherence, medications’ active ingredients and excipients. Patients’ self-
reporting was the appropriate tool for collecting the ADRs that was influenced by 
patients’ characteristics, concurrent diseases, and medications’ active ingredients and 
excipients. Polypharmacy of excipients must be taken in the consideration when
conducting the clinical studies. Also, interventional programs are needed to improve 
healthcare professionals’ knowledge about pharmaceutical excipients.
CHAPTER 1
INTRODUCTION 
1. Background
1.1 Dyslipidemia
Dyslipidemia means the abnormal changes for one or more of lipids in the 
blood (NCEP, 2001). It is considered as strong predictor and pathogenic factor for 
common cardiovascular problems. There is significant relationship between blood 
cholesterol level and incidence of cardiac diseases, reduction of 1% cholesterol level 
decreases 1% incidence of cardiac diseases (Neaton et al., 1992; 4S study, 1994
Grundy et al., 2004).
1.2 Types of dyslipidemia 
Two types of dyslipidemia mentioned by the literatures, these are primary and 
secondary. These types characterized by differences in levels of lipoproteins and 
cholesterol.
1.2.1 Primary dyslipidemia 
It is caused by either single or multiple genetic changes induced
overproduction and/or defects in the clearance of cholesterol, triglyceride (TG), low 
density lipoprotein (LDL), or due to higher clearance of high density lipoprotein 
(HDL). This type of dyslipidemia was discovered by Fredrickson and Friedewald
(Friedewald et al., 1972; NCEP, 2001; American Diabetes Association, 2006), and 
classified into subtypes as shown in Table 1.1
Table 1.1 Types and properties of primary dyslipidemia (Friedewald et al., 1972)
Type Elevated lipoproteins Elevated lipids
I  Primary hyperlipoproteinemia or Familial 
hyperchylomicronemia
Chylomicron TGs
IIa Polygenic hypercholesterolemia or 
Familial hypercholesterolemia
LDL Cholesterol
IIb  Combined hyperlipidemia LDL and VLDL TGs and cholesterol
III   Familial dysbetalipoproteinemia VLDL (VLDL:TG ratio > 0.3)
and  Chylomicron 
TGs and cholesterol
IV Endogenous hyperlipidemia VLDL TGs
V  Familial hypertriglyceridemia Chylomicron and VLDL TGs and cholesterol
TG= Triglyceride, HDL=High density lipoprotein, LDL=low density lipoprotein, VLDL= very 
low density lipoprotein
1.2.2 Secondary dyslipidemia 
This type of dyslipidemia caused either by diseases like diabetes mellitus, 
hypothyroidism, hepatic diseases, renal insufficiency, pregnancy and systemic lupus, 
or chronic use of alcohol, estrogen, or therapy with antihypertensives like beta 
blockers and thiazides 1&(3Stone et al., 2008) as shown in Table 1.2
Table 1.2 Types and properties of secondary dyslipidemia (Stone et al., 2008)
Disorder Cholesterol TG HDL LDL VLDL Chylomicron Other 
tests
Renal failure Unchanged Increased Decreased Unchanged Increased Unchanged SCr
Nephrotic 
syndrome
Increased Unchanged Unchanged Increased Unchanged Unchanged
Hypothyroidism Increased Increased Unchanged Increased Unchanged Increased TSH
Type 2 diabetes Increased Increased Decreased Increased Increased Increased Glucose
Obstructive liver 
disease
Increased Unchanged Unchanged Increased Unchanged Unchanged Liver 
function
Ethanol use Unchanged Increased Unchanged Unchanged Increased Unchanged
Pregnancy Increased Increased̅ Unchanged Increased Increased Unchanged
Systemic lupus Unchanged Increased Unchanged Unchanged Unchanged Increased
Drug 
use
Diuretic
B-BK
Estrogen
Cyclosporine
Increased
Unchanged
Unchanged
Increased
Unchanged
Increased
Increased
Unchanged
Unchanged 
Decreased
Unchanged
Unchanged
Increased
Unchanged
Unchanged
Increased
Unchanged
Increased
Increased
Unchanged
Unchanged
Unchanged
Unchanged
Unchanged
* Increased only in third trimester, SCr = Serum creatinine, TSH = Thyroid 
stimulating hormone
1.3 Dyslipidemia control
Reports of National Cholesterol Education Program (NCEP) in US found that 
elevation of cholesterol is the main cause for cardiac diseases like stroke, myocardial 
infarction…etc. The main parameters that needed to be controlled according to the 
Adult Treatment Panel (ATP) III report of NCEP are LDL and non-HDL (refers to 
total cholesterol excluding HDL) (Ballantyne et al., 2001; NCEP, 2001).
Lipid profile is usually determined by calculating LDL, which can be 
measured by using the Friedewald equation (equation 1.1). Very low density 
lipoprotein (VLDL) is equal to TG/2.2 (the equation is considered invalid when the 
amount of TG more than 4.5 mmol/l). The non-HDL can be calculated directly from 
the equation no 1.2.
LDL (mmol/l) = TC – HDL-C + TG/2.2 ... (1.1) (adapted from Bernard et al., 2002) 
non-HDL = TC – HDL ……….. (1.2)   (adapted from Koda-Kmble, 2005)  
1.4 Targets of dyslipidemia control
The control of dyslipidemia depended mainly on two parameters, LDL and 
non-HDL as reported by the NCEP ATP report III (NCEP, 2001). The goal of 
therapy to achieve these goals depended on the patient's health risks. These risks are 
classified into primary and secondary preventions. 
        Secondary prevention means the patients under the existed risks because of 
cardiac diseases or equivalent, which includes:
1- Clinical CHD myocardial ischemia, MI, coronary bypass graft and prior 
unstable angina.
2- Carotid artery diseases: stroke history, transient ischemia attack.
3- Peripheral arterial diseases.
4- Abdominal aortic aneurysm.
5- Diabetes mellitus.
Primary prevention means the expected risk of the patient in the future which 
depended on several parameters like gender, age, family history of CHD, 
hypertension, total cholesterol, HDL, and smoking (LaCroix et al., 1991; Stamler et 
al., 1993; Wilson, 1998; van den Hoogen et al., 2000).
NCEP instructed the goals of therapy needed to control the dyslipidemia and 
prevent the cardiovascular diseases, for both LDL and non-HDL as shown in Table 
1.3.
Table 1.3 Targets of dyslipidemia control according to the NCEP reports
(NCEP, 2001)
LDL goals non-HDL goals
Prevention
mg/dl mmol/l mg/dl mmol/l
Primary <130 <3.4 < 160 < 4.16
Secondary <100 <2.6 <130 <3.4
Secondary dyslipidemia showed higher importance depending on the 
recommendations and results of the previous reports and studies because the 
relationship is significant between the targets and diseases. LDL elevation more than 
100 mg/dl was correlated with the incidence of cardiovascular diseases (4S, 1994; 
Sacks et al., 1996; LIPID, 1998). Therefore goal of therapy for patients with 
secondary prevention must be less than 100mg/dl (2.6 mmol/l) (Nissen et al. 2004),
while risk of patients with primary prevention reduced when LDL level was less than 
129 mg/dl (3.4 mmol/l) (NCEP, 2001; Pearson et al., 2003).
1.5 Assessment of lipid profile 
According to NCEP reports, the lipid profile can be assessed to optimal, 
desirable, borderline high, high and very high depending on the levels of lipids as 
shown in the Table 1.4
Table 1.4 Type of dyslipidemia and assessment categorization (NCEP, 2001)
lipoproteins Level (mg/dl) Level (mmol/l) Categories 
< 200 < 5.2 Desirable
200–239 5.2-6.2 Borderline highTC
≥ 240  > 6.2 High
< 100  < 2.6 Optimal
100–129 2.6-3.36 Near optimal/above optimal
130–159 3.37-4.11 Borderline high
160–189 4.12-4.91 High
LDL
≥ 190  > 4.92 Very high
< 40  <1.05 Low*HDL
≥ 60 >1.6 High**
< 150 <1.7 Desirable
150–199 1.7-2.3 Borderline high
200–499 2.31-5.6 High
TG
≥ 500  >5.7 Very high
Note :** HDL > 1.6 is a negative risk factor 
*  HDL < 1.05 is a positive risk factor
1.6 Antihyperlipidemics
Many antihyperlipidemics are used to achieve the control of dyslipidemia. 
Therefore, these medications are used either as single or in combination therapy. 
These medications are statins, niacin, ezetimibe, resin, fibrates, and fish oil. Among 
all these medications, statins are the more common use for cardiac patients because 
the highest efficacy according NCEP ATP reports (NCEP, 2001).
1.6.1 Statins
Statins are considered as the drug of choice for treatment of dyslipidemia and 
as prophylaxis against many cardiovascular diseases. Statins are inhibitors of 3-
hydroxy-3-methylglutaryl-CoA (HMG CoA) reductase which involved in the 
cholesterol synthesis (Goldstein and Brown, 1990; Grundy et al.NCEP, 2001;
Vaughan and Gotto, 2004).
1.6.2 Types of statins
          Statins include atorvastatin, simvastatin, rosuvastatin, lovastatin, pravastatin, 
fluvastatin, and cerivastatin. The last type of statin was banned from the market 
because serious adverse drug reactions (ADRs). Eventhough, these types of statin are 
different in their efficacy due to the difference in the pharmacokinetic properties like 
bioavailability, lipophilicity, half life, and excretion (Jones et al., 1998; Peter, 2003).  
1.7 Uncontrolled dyslipidemia during therapy
          Several reasons are correlated to inability to achieve dyslipidemia control 
during therapy; however few studies were focused on physicians’ practice, patients’ 
adherence and treatment adverse metabolic effects.
1.7.1 Physician's knowledge and practice
One of the reasons for failure of dyslipidemia therapy is the knowledge and 
awareness of physicians, because lacking in updated information resources such as
reports and studies in assessing the patient properly and prescribing the optimal 
therapy (Sager et al., 2010). Therefore physicians were needed for specific updated 
guidelines, based on the previous studies, about the significant required changes in 
the medications and regimens toward complications during therapy. The benefit of 
guidelines is improving the knowledge and decisions making of physicians after 
assessing and evaluating the patient's health status and the ways of managing the 
expected risks faced particularly in cardiovascular field. This is because 
cardiovascular diseases are considered number one cause of death for patients in 
many countries (Davidson, 2002; Pearson et al., 2002; Davidson et al., 2005; Asch et 
al.'RURRGFKL
NCEP recommendations to control of dyslipidemia obligated the physicians to 
determine the risks and how to prescribe the specific medications for this type of risk 
(Sheridan, 2003). Physicians' knowledge and awareness toward dyslipidemia 
guidelines are contributed to achieve the targets of control in health care system, 
where proportional relationship between physicians' knowledge and the improved 
patients' health status (Foley et al., 2003; Heidrich et al., 2005). Recent programs are 
used nowadays in order to achieve the goals of therapy. Invented educational 
programs and management algorithms were implemented to obtain optimal 
assessment of control. The effective program depended on development of the old 
dyslipidemia guidelines of control like physicians' knowledge about the primary and 
secondary prevention, and programs of lifestyle changes such as nutrition and 
exercises (Goldberg et al., 2007).
Different guidelines are followed in different countries, but the knowledge is 
the main tool to get the optimal result and improve the health status of patients. Some 
systems depended on computer to calculate the risk and the intervention needed to 
attain the goals of therapy, while other on physicians' performance to calculate these 
risks. Recently many inventions and programs were introduced in developed 
countries to facilitate and provide accurate evaluations, assessments, and treatment. 
The main reason was belonged to the practice and knowledge of physicians toward 
control of dyslipidemia and prophylaxis against the cardiovascular diseases (Hetlevik
et al. Murray et al., 2004; Davidson et al., 2005). Thus physicians' awareness 
in developed countries is significant to achieve the targets of dyslipidemia control
(Erhardt and Hobbs, 2007; Cacoub et al., 2008), while low control found in 
undeveloped countries was due to poor or average of physicians' knowledge toward 
the goals of therapy (Al-Omran, 2007).
Many physicians did not follow the instructions recommended by NCEP 
reports, allowing themselves prescribing the dosage regimens depending on their 
own experience which later cause fluctuation in control of dyslipidemia. To give an 
example, not all physicians believed that LDL is the main risk of cardiovascular 
diseases if compared to total cholesterol (Goldberg et al., 2007). Most of family 
physicians have differences in their knowledge towards the requirements to control 
dyslipidemia and other cardiovascular diseases (Eaton et al., 2004). Previous studies 
showed poor knowledge of physicians in assessing the expected risks and 
medications regimens required to avoid the morbidities and mortalities, as well as, 
the evaluation of patients' health status and adherence (Mosca et al., 2005).
Many international studies showed failure of achieving the goals of therapy, 
even patients were on the ideal guidelines and with good adherence to therapy. This
is because most of physicians were motivated to prescribe higher doses of statin to
attain the goals of therapy. Inversely, the patients' acceptance and confusion to use 
higher doses may reflect on their adherence to the prescribed medications, causing 
lower percentage of dyslipidemia control (EUROASPIRE II Study Group, 2001). On 
another view, physicians believed that higher dose of statin will achieve the predicted 
reduction of cholesterol to be in the healthy range, without determining the main 
reasons for the elevations of cholesterol (Schwandt and Brady Van Ganse et 
al., 2005)
Physicians are knowledgeable towards the adverse effects of common
medicines like elevation of liver enzymes or renal disorders, but not to adverse 
effects of other medications like statins (Davidson et al., Erhardt and Hobbs, 
Guan et al., 2010). Studies reported that many physicians claimed that patient 
is the main cause of uncontrolled dyslipidemia either by not following their
instructions like restricted diet and changing of life style, or due to the high cost of 
medications which affected on their adherence (Eaton et al., 2006). Other studies 

stated patients’ related complaints for adverse effects of medications with higher 
doses and chronic therapy which triggered them either stopping usage or asking for
changing of these medications (Pasternak et al., 2004). As a result for the physicians' 
and patients' factors, new barrier observes is the responsiveness and efficacy of 
medications (Mosca et al.Christian, 2006). The main objective of all previous 
studies was to eliminate the barriers and obstacles toward attaining the ideal result of 
dyslipidemia control sharing that with other healthcare professionals like pharmacists 
and nurses (Goldberg et al., 2007). A gap found between physicians’ knowledge and 
control of dyslipidemia; very low incidence of patient with CHD risks or risk 
equivalent found under control, while physicians claimed that most of their patients 
were controlled during the first years (Pearson, 2000; Mosca et al., 2005). Depending 
on previous studies of dyslipidemia control, the patients with uncontrolled were
correlated with the physicians who failed in estimation of the correct goal of therapy 
and prescribing of medications (0RQWJRPHU\ Hirsch et al., 2001; Hajjar and 
.RWFKHQPignone, 2003; Sheridan, 2003; Saydah et al., 2004).
Second reason which believed to be contributed in the elevations of cholesterol
and failure of treatment is insufficient number of recommended lipid profile tests 
performed to the cardiac patients which is considered as another commitment to the
physicians toward their patients. Several reports and studies recommended increasing
the number of lipid profile tests for patients per year and depending on the patients' 
health stability (Gold, 2004). There is responsibility of physicians for advising their 
patients about lifestyle and dietary therapy to control the dyslipidemia and 
cardiovascular diseases, because some habits like eating, smoking and consuming of 
alcohol may change the goals of therapy and aggravate the cardiovascular risks. 

However, many physicians are not performing their non-pharmacological therapy, 
for example no difference between the physicians' dietary therapy and common 
smoking advices (Mukherjee et al.Olson et al. Doroodchi et al., 2008; 
Sheridan and Crespo, 2008). Some of physicians' characteristics play role in 
enhancement of patients’ health status such as years of experience, age, gender, and 
location of work. Some studies proved that old physicians had good experience in 
administration of therapy, but they are in lower adherence to the updated researches. 
Also, the awareness of the rural physicians is lower than urban which affects on the 
medical improvement of the patient (Doroodchi et al., 2008).
1.7.2 Patients’ adherence to dyslipidemia therapy
World Health Organization (WHO) defined the patients’ adherence for long 
term as “the extent to which a person’s behavior taking a medicine, following a diet, 
and/or executing lifestyle changes - corresponds with agreed recommendations from 
a health care provider”. Patients’ adherence means the compliance to their 
physicians’ orders related to strategy of therapy (Rigby, 2007). It is considered one 
of serious problems related to achieve the goals of therapy to avoid the relapse or 
failure of therapy (Natarajan et al., 2007). Failure of therapy was mostly happened in 
elderly patients who used multiple medications for very long time (Senior et al., 
2004). Many studies highlighted the common reasons of discontinuation of therapy 
because adverse drug reactions, cost of medications, psychological acceptance and 
many others (Vermeire et al., 2001). Several methods were used in evaluation of 
patients’ adherence either by direct effect of drug on blood drug concentration or 
indirect by questionnaires, pill count, refill rates, counseling, follow-up reminders 
and physiological parameters like cholesterol level (Osterberg and Blaschke, 2005). 

Therefore tools were invented to assess the adherence of patients toward their 
therapy. The most useful and efficient scale was that of Morisky scale which used by 
many studies related to therapy of diabetes, hypertension and dyslipidemia (Morisky, 
1986).
Several authors stated the relationship between patients’ adherence and 
achieving the goals of therapy of dyslipidemia and maintain patients’ life against 
cardiovascular risks (Kiortsis et al., 2000). The number of patients were taken statin 
properly and regularly found with fewer incidences of cardiovascular risks and 
mortality (Heart Protection Study Collaborative Group, 2002). Kiortsis and 
colleagues declared that good hypercholesterolemia therapy adherents were old, none 
or seldom smoking patients, complained fewer adverse reactions, and those were 
regularly attended their appointments with doctors and used proper dosage regimens 
(Kiotrsis et al., 2000). 
Shalev V et al. found that patients with suboptimal adherence to statin therapy 
had got suboptimal LDL control (Shalev et al., 2009). The discontinuation of statin 
therapy was also differently reported from study to another, but according to 
previous studies the rate of discontinuation ranged between 30-70% (Sokol et al., 
3HQQLQJ-van Beest et al.3HUUHDXOW6KDOHY et al., 2009). However 
all these studies stated significant positive correlation between the duration of 
therapy and incidence of patients stopped taking their therapy (Benner et al., 2002).
To give some examples, Insull W. stated that incidence of patients discontinued 
statin therapy ranged 6-30% after five years (Insull, 1997). Australian Institute of 
Health and Welfare (AIHW) reported the incidence of patients discontinued their 

therapy after six months was 10-28% which was raised to be 21-47% after 24 months 
(Rigby, 2007). While other studies stated unexpectedly low adherence with 
unexpected range of discontinuation; adherence to statin therapy was 50-85% after 
the first year and 45-50% after the fifth year (Newby et al., 2006; Kulik et al., 2011). 
Latry et al. believed that patients’ poor adherence to lipid lowering agents was 
mainly affected by their characteristics such as gender, concurrent medication and 
diseases, but very few studies discussed the other cofactors related to adherence
(Latry et al., 2011). Another reason was related to physicians, Schedlbauer A et al.
correlated between the physicians’ performance and their patients’ adherence to lipid 
lowering agents, where improvement of patients’ adherence was seen after 
intervention given for physicians (Schedlbauer et al., 2004). Another important cause 
for rate of discontinuation of statin is the cost factor. Several studies highlighted the 
relationship between the cost of medication and adherence rate. Interestingly the 
good adherence reduced the overall cost due to significant improvement of health 
patients’ status and might be lower admissions or re-prescribing of new medications 
(Corrao et al., 2011).
1.7.3 Common cardiac active ingredients and dyslipidemia
There were active ingredients that induced abnormal changes of lipid profile 
which were classified as secondary type of dyslipidemia (Stone et al., 2008). All 
active ingredients were different in percentage of lipid profile changes; some 
increase, decrease or others unchanged, i.e. some may increase LDL while 
unchanged to HDL and so on. Many antihypertensives interact with lipid metabolism 
caused alterations in lipid profile like LDL, HDL, TG and TC, which they worsened 
patients’ cardiac risks within the first year of therapy and minimizing the beneficial 

effect of lipid lowering agents (Krone et al., 1983; Rohlfing and Brunzell, 1986; 
Weidmann et al.Grimm, 1990; Rabkin, 1993; Madu, 1996; Patel and Jackson, 
2010). Ballantyne believed that long-term of thiazide diuretics was associated to
higher incidence of atherosclerosis because observed elevation in LDL and dropping 
in HDL level (Ballantyne, 1990). Moreover, authors stated uncontrolled dyslipidemia
within long duration of diuretic therapy, because the adverse metabolic indirect 
effect of these medication to patients’ lipid profile (Ames, 198 Ames, 1988; 
Lardinois and Neuman, 1988). Others found association between incidence of 
mortality and long term using high doses of thiazides and beta blockers, because 
affecting the insulin resistance, release of glucose and elevation of LDL cholesterol
(Teuscher and Weidmann, 1997; Sarafidis and Bakris, 2006).
Lijnen and colleagues stated the mechanisms for the worst antihypertensive 
type, the thiazides, which induced biochemical changes by inhibiting phosphor-
diesterase enzyme and inducing lipolysis (Lijnen et al., 1989). Weir and Moser
revealed other mechanisms of diuretics; first by decreasing the insulin sensitivity 
causing higher production of cholesterol, and second by lowering the potassium level 
during thiazide therapy (Weir and Moser, 2000). However the adverse metabolic 
effect of thiazides was more predictable for patients following therapy up to 4 years 
(ALLHAT Collaborative Research Group, 2002). Calcium channel and beta blockers 
were also correlated to change of lipid profile by different mechanisms such as 
affecting cellular lipid metabolism, lipase dysfunction, and LDL receptors (Krone W 
et al., 1987; Wolinsky, 1987; Lijnen et al., 1989). A stimulation of alpha adrenergic 
receptors as result of blocking beta receptors caused reducing the activity of lipase 
enzyme and catabolism of TG, VLDL, and then reduced the HDL level (Weir and
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Moser, 2000). Also it noticed there is no relationship between abnormality of lipid 
profile and selectivity type of beta blockers, both selected and non-selected drugs
increased TG and reduced HDL levels (Lehtonen, 1985; Hunninghake, 1991). Sharp
et al. explored the adverse metabolic effects of antihypertensives in twelve studies
concluded changes of lipid profile induced by carvidolol comparing with selective 
beta blockers. So they recommended for choosing the appropriate antihypertensive 
type because it also attributed for therapy failure of dyslipidemia, hypertension and 
congestive heart failure (Sharp et al., 2008). Cooper-DeHoff found significant 
increase in patients’ body weight and triglyceride during therapy of beta blockers and 
hydrochlorthiazide (Cooper-DeHoff et al., 2010). As well as, these antihypertensives 
were different in increments of certain lipid (Rouffy et al., 1984). To give example 
spironololactone is the lowest adverse lipid elevator when compared to other types of 
diuretics (Ames, 1988). Some authors believed that changes of lipid profile were
mostly attributed to the dose of administrated antihypertensive medications (Weirand
Moser, 2000).
Inversely some studies found antihypertensive medications, such as alpha 
blockers, reduced the total cholesterol and improved HDL level by stimulating 
carbohydrate and lipid metabolism, reducing glucose, LDL, VLDL and improving 
HDL (Waite, 1991). Ashida found Angiotensin-converting enzyme inhibitors (ACE-
I) and angiotensin II receptor blockers (ARB) have neutral effect toward cholesterol 
(Ashida, 2001). Other studies predicted the neutrality and positive lowering effect of
some antihypertensives compared to lipid elevating medications, a reduction and 
better control of cholesterol during administration of calcium channel blockers, 
ARBs and ACE-Is (Brook Papademetriou, 2007; Nouri-Majalan et al., 2009).

Recent studies insisted about the possible interactions of antihypertensive 
medications with lipid profile changes. Diltiazem inhibited the activity of CYP3A 
causing better efficacy of statin and more reduction in LDL level (You et al., 2010).
Therefore selectivity of antihypertensives must be considered during prescribing the 
ideal medication to control hypertension with lowest adverse metabolic effects 
(Salvetti A and Ghiadoni, 2006).
1.8 Definition of the excipient
          There are several definitions of excipients mentioned by many previous 
reports. According to the common definition mentioned by the National Formulary 
Admission Policy that "Excipients are any component other than the active 
substance(s) intentionally added to the formulation of a dosage form" (USP, 1992). 
Another definition in term of pharmaceutical manufacturing by Steinberg, "any 
material used in the preparation or formulation of a finished drug dosage form, other 
than the active pharmacological agent", and the new excipient is "a compound which 
has not been previously used or permitted for use in a pharmaceutical preparation"
(Steinberg et al., 1996). There is another definition in point of view of the safety and 
toxicity by International Pharmaceutical Excipients Council (IPEC) of America for 
the excipient, which is defined as "Any substance other than the active drug or 
prodrug which has been appropriately evaluated for safety and is included in a drug 
delivery system" (Steinberg et al., 1996). 

1.8.1 Benefits of excipients
All medications must have excipients that perform a function inside the dosage 
form to enable the medications to work properly inside the human body. Number of 
active ingredients in each dosage form is lower if compared with number of 
excipients The main sources of excipients are either naturally or synthetically, and
different in their nature i.e. organic or inorganic (Bhattacharyya et al., 2006). IPEC 
determined the functions and requirements for using of excipients in manufacturing 
of medications (Steinberg et al., 1996), these are: (1) support the system of 
manufacturing, (2) enhance or improve the palatability, stability, solubility and 
bioavailability, (3) support the identification of medication, and (4) supply the 
evidences of its safety and efficacy. The main functions of excipients are to advance 
the properties of the dosage form and bioavailability. The excipients are used for a 
function inside the formulation to make its performance better and targeted, these 
materials  are; (1) fillers or  diluents,  (2) binders, (3) disintegrants  or super 
disintegrants, (4) lubricants, (5) antiadherents, (6) glidants, (7) wetting and surface 
active agents, (8) colors and pigments, and (9) flavors, sweeteners, and taste maskers 
&KRZDQ Wheatley, 2000; Bhattacharyya, 2006). Some excipients have been 
used to a specific function in its dosage form, work as antimicrobial which react with 
oxygen to inhibit the contamination of medication or food such as sulfites (Bush et 
al., 1986), or to improve the acceptability by patients in term of palatability or color. 
Some excipients used to activate the active ingredient, for example polyethylene 
glycol (PEG) added to enhance the activity and bioavailability of calcium channel 
blockers or benzodiazepines (Hjortkjaer et al.5DKPDQDQG/DX-Cam, 1999).

Excipient were also classified in to three classes based on their common use;
established (approved), new (novel), and essentially new excipients (from other 
industries). The first class referred to the known excipients which had been used for 
long time in pharmaceutical preparations. The first twelve common excipients among 
800 substances used  in  US  are; water,  magnesium stearate,  starch,  lactose, 
microcrystalline cellulose, stearic acid, sucrose, talc, silicon dioxide, gelatin, acacia,
dibasic calcium phosphate, and sugar free excipients. Approvals of new excipients 
depended on preclinical studies which are different from country to another. For 
example some new excipients are not found in US (CDER) or Japan but use in 
Europe (Brown, 196KDQJUDZ Center for Drug Evaluation and Research, 
 DeGeorge et al., 1997; Japanese Technical Requirements for New Drug 
RegistrationBaldrick, 2000; Bhattacharyya, 2006). 
Based on previous reports for manufacturing of medications, changes of 
excipients in dosage forms cause changes in results of their standardization, which 
make companies to look for new excipients for new formulations as new products. 
Furthermore, the companies need to prepare the clinical trial studies about the safety 
of new pharmaceutical excipients, and appropriateness to the other ingredients in
dosage form (Pifferi et al., 1999). Although significant developments in 
manufacturing of medications, many of excipients still cause fatal problems such as
bladder tumor and adrenal/testes problems due to saccharine and polyols 
respectively, and some derivatives of cyclodextranes may cause renal dysfunctions 
+HUEHUW7KRPSVRQMosher and Thompson, 2000).

1.8.2 Safety of excipients
          Everything related to manufacturing of medications must be supervised by a 
main organization to control the using of excipients, called The International 
Pharmaceutical Excipients Council (IPEC). This organization approves the 
memberships of the companies, manufacturing, and use of chemicals and excipients. 
It has also many branches over the world, such as in US, Europe and Asia. Therefore, 
the new excipients must be approved by the IPEC to ensure the safety and toxicity of 
the new products.  The safety committee of the IPEC is responsible to conduct the 
studies related to toxicity of the excipients, especially the animal studies and human 
with chronic exposure to excipients (Steinberg et al., 1996). In the world, including 
developed countries, there are no regulations of registration for the excipients as a 
separate entity, neglecting the activity and safety of the excipients. FDA started to 
test all the medications in US for both active ingredients and excipients of 
formulations, for getting the full details of their safety and efficacy (Brown, 1983).
Most of the toxicities and adverse drug reactions correlated mainly with the 
pharmacokinetic of all excipients, and some with pharmacodynamic for few 
excipients. The studies search the pharmacokinetic of active ingredients and 
excipients called Toxicokinetics, which related with the absorption, distribution, 
metabolism, and excretion of these chemicals. Excipients are similar to active 
ingredients in their pharmacokinetics but there is difference in percentages of 
absorption, distribution... etc. This difference allow some excipients to exert their 
adverse effects and other parameters of toxicity, for example, some of excipients 
may pass the blood brain barrier, placenta, testis barrier, which likelihood cause 
some adverse reactions in the related areas. The absorption of the excipients is

varying depending on the physicochemical properties of these excipients. To give 
example, high molecular weight compounds lack to the absorption property, so they 
are without systemic effect, but it may cause gastrointestinal adverse effects. There is 
another factor related with pharmacokinetics is the age of the user, which refers to 
the pharmacokinetic and physiological changes of elderly persons, and their effects 
on absorption of both active ingredients and excipients. However, these parameters 
of toxicokinetics are different among the animal species if compared to humans
(Frank et al., 2000). 
There are types of experiments that must be done to approve the safety of the 
excipients after manufacturing, however the human studies depended mostly on the 
single dose treatment. The safety must cover the carcinogenicity and mutagenicity 
like fertility and embryo fatality, as well as, the chronic use must be applied for 3 
months as maximum and must be done on animals only (U.S. Federal Food, Drug, 
and  Cosmetic  Act,  Steinberg, 1996). Most of excipients used in the 
formulations are safe in terms of teratogenicity and carcinogenicity, but there are 
exceptions about some excipients which can not considered as safe materials like 
narrow safety margins' materials (Golightly et al., 1988). These types of preclinical 
VWXGLHVWKDWPXVWEHDSSOLHGEHIRUHXVHRIH[FLSLHQWVDUHGD\VWKHUDS\RUOHVV
infrequent use, repeated dose toxicity and this must be applied on two mammalians 
for one month (Davis, 2006). The IPEC and the FDA are responsible to determine 
the strategy of preclinical studies, depending on the duration and strength of 
seriousness (Osterberg and See, 2003). Most of excipients previously tested to be 
safe for teratogenicity and carcinogenicity or with minimal toxicity when tested in 
animals. Eventhough, some excipients induced severe adverse reactions like nasal 

toxicity due to ethylene glycols, maternal toxicity by corn oil, renal and liver toxicity 
in rats by cyclodextrines, renal dysfunction with proteinuria by dibasic sodium 
phosphate, increase in triglycerides and cholesterol by Poloxamer (P-407), and
maternal and embryo toxicity by propylene glycol. Polyvinyl acetate phthalate
(PVAP) cause gastrointestinal tract irritations. Tartaric acid caused diarrhea, emesis, 
and fall of blood pressure in dogs and nephrotoxicity in monkeys. Also 
pharmaceutical excipients of parenteral formulations caused hemolytic changes. 
Regrettably the preclinical studies are given the minimal evidence about the safety of 
H[FLSLHQWVDQGRWKHUPHGLFDWLRQV%DOGULFNRobert, 2006). 
Most of healthcare professionals believed that testing in animals is safe to be 
used by human. Although many studies applied on animals to show the safety of 
excipients but the results found in animals are different with humans. In other word, 
it is not possible to generalize these results of these healthy animals to elderly human
patients (Napke, 1994). Moreover, there are differences in species between human 
and other animals in metabolism, which affect on the activities of excipients and then 
safety and ADRs. Thus there was inadequate information about the metabolism of 
excipients in human if compared to animals. Some of excipients and active 
ingredients are good absorbed in human and poor in animals which later affect on the 
safety and ADRs, and vice versa. For example, cyclamate is metabolized in human's 
intestine forming toxic substance cyclohexylamine which not formed in animals,
therefore its toxicity disappeared due to differences in the metabolism occurred in 
bowel (Bopp et al., 1986; Frank, 2000).

The development in manufacturing of new dosage forms was followed by 
many changes in the old excipients, which later changed in their activity and safety
and needed to be retested again. Most of new invented excipients had got new 
properties like enhancing the function of excipients or by having multiple functions 
in same time, but not focused on the new adverse reactions and toxicities (Pifferi et 
al., 1999). As well as, there was difference in incidence of toxicity induced by 
excipients depending on type of dosage form (oral, parenteral, transdermal …etc). 
For the most popular dosage form, oral forms, it required some tests to approve the 
H[FLSLHQWVOLNHDFXWHRUDOWR[LFLW\GD\VWR[LFLW\WHUDWRJHQLFLW\DQGFKURQLFXVH  in 
animals, chromosomal damages and mutations, and skin problems. There is 
challenge about excipients and their safety in human, because first it is impossible to 
perform studies in human using new excipients. Second the safety and activity of 
excipients are different from dosage form to another, therefore it is not possible to 
say that this excipient is safe in all dosage forms. As example, some authors 
recommended for changing of human serum albumin to polysorbate 80 because it 
influenced on immunogenicity of the proteins medications (Sharma, 2007). 
Some new excipients without full reports about their safety and toxicity are 
added in the manufacturing of medications to do a function in the dosage form. For 
example, some excipients used in the prodrug formulation, or to enhance the efficacy 
of medications like chitosan, or in monoclonal antibodies that considered as new 
dosage forms. There are many other factors influence and motivate the toxicities in 
human body, like the impurities of excipients used or due to the excipients 
interactions (Nema et al., 2002). Many of the excipients used by the food 
manufacturing are used in pharmaceutical medications too which helped the 

manufacturers to consider these excipients as safe, but some differences found like
the period of exposure and then safety. This is because most of excipients tested for 
not more than 6 weeks to show safety and not all excipients are taken by people 
continuously and for long duration concurrently with diseases. Second, the food's 
excipients are used by oral route only which excluded pharmaceutical excipients of 
other routes. Third, standardizations of pharmaceutical excipients in dosage forms 
are higher than food one, because food excipients are not standards with less purity 
(Ja¨kel and Keck, 2000). In Japan, all the excipients used in manufacturing of food
considered as new excipients in manufacturing of pharmaceutical products
(Uchiyama, 1999).
Manufacturers believed that pharmaceutical excipients are safe and harmless to 
human body, because most of their serious adverse reactions were not predicted yet. 
Also, the multiple numbers of excipients taken by patients had showed inability to 
diagnose the problems caused by excipients in clinical trial studies (Napke, 1994). 
To give a good example about unsafe excipient, lactose is commonly found in food 
and pharmaceutical preparations, and its incidence of intolerance or sensitivity of
white patients was 5% to 15%, while for other races was 60% - 90%. Lactose also 
contributed for high incidence of abdominal distension and diarrhea after lactose 
ingestion (Toskes, 1992). So, how many studies involved animals ingested with 
lactose as placebo or patients used lactose dosage forms, and what its effects on the
studies’ outcomes (Napke, 1994). 
Even the small doses of excipients presented in dosage forms and taken by 
patient, but always there is minimal adverse reactions were predicted, as found 

during use of benzalkonium chloride that not showed ADRs in the first dose 
(Rafferty et al. O’Driscoll et al., 1989). However, the toxicity for some 
excipients was independent to the concentration especially those with multiple 
functions. For example, benzyl alcohol used as preservative and solubilizer, and
decomposed into hydrogen peroxide and benzaldehyde but adverse reactions are 
different than main compound (Ja¨kel and Keck, 2000).
Governments and health organizations obligated manufacturing companies in 
developed countries to disclose the full details of their products to the patients and 
healthcare professionals to avoid problems found during therapy (Napke, 1994). 
Previous study showed evidence of adverse drug reactions of excipients; patients 
with Addison disease were more comfortable to one brand and complained new 
ADRs after changing to another brand. Main reasons are either direct by the 
excipients themselves or indirect because changeable parameters of bioavailability of 
the active ingredient (Whittet, 1971). Thus conducting of clinical studies is required,
focusing on the long duration of therapy especially the new excipients found in 
medications' dosage forms (Spire et al., 2003). Trial studies are burdens for the 
manufacturers because of reliable results of equivalence and safety, but in case of 
multiple doses with multiple medications in chronic use by ill patients, this opinion 
shows some limitations (Castle et al., 1969). Edward Napke believed there is 
deficiency in reported information of ADRs in hospitals, and need for development 
of ADR surveillance system, especially related to excipients and their ADRs because 
the system information is only related to active ingredients (Napke, 1994; Anderson 
et al., 2006). 
